RecruitingCryopreservationOvary InjuryInfertility, Female
Improving the Quality of Cryopreserved Ovarian Tissue Reimplantation Using Platelet-enriched Autologous Plasma
Eligible age
All ages
Accepts
Women
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The study is aimed to evaluate the effects of intraovarian injection of autologous Platelet-enriched Autologous Plasma on the outcomes of orthotopic transplantation of cryopreserved ovarian tissue.
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
You may qualify if…
- ✓ request for cryopreserved ovarian tissue transplantation;
- ✓ premature ovarian failure or irregular mentrual cycles;
- ✓ negative test for HIV, HBV, HCV, Treponema pallidum;
- ✓ negative PAP test;
- ✓ oncological authorization;
- ✓ absence of neoplastic contamination in the cryopreserved ovarian tissue;
- ✓ Informed consent
You may not qualify if…
- ✕ neoplastic contamination in cryopreserved ovarian tissue;
- ✕ history of endometriosis;
- ✕ endocrinological disorders present and not treated (uncompensated thyroid dysfunction, diabetes (type 1, type 2);
- ✕ body mass index (BMI) \>30 kg/m2;
- ✕ circulating platelet level \< 150,000 / mml;
- ✕ bacterial infection;
- ✕ ongoing use of anticoagulants;
- ✕ bleeding diathesis.
Source: ClinicalTrials.gov · NCT06261658 · last updated 2024-02-15